Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Head & Neck Cancer Specialty Channel

Head & Neck Cancer
Specialty Channel
News
First-Line Pembrolizumab Plus Chemotherapy Showed Promise Among Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/26/2024
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the...
07/26/2024
Oncology
Conference Coverage
Addition of Nivolumab to Triple Metronomic Chemotherapy Significantly Improved Overall Survival Among Patients With Advanced Head and Neck Squamous Cell Carcinoma
06/20/2024

Stephanie Holland 

Stephanie Holland 
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose...
06/20/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
Conference Coverage
Tisotumab Vedotin Showed Promising Clinical Activity Among Heavily Pretreated Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
06/11/2024

Stephanie Holland 

Stephanie Holland 
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results...
06/11/2024
Oncology
News
Addition of Vismodegib to Radiation Therapy Shows Promise Among Patients With Basal Cell Carcinoma
05/10/2024

Stephanie Holland 

Stephanie Holland 
Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.
Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.
Results from a prospective,...
05/10/2024
Oncology
News
Radiotherapy Alone After Chemotherapy Induction for Patients With Nasopharyngeal Carcinoma
02/23/2024

Allison Casey

Allison Casey
According to results from a phase 3 trial, radiotherapy alone was noninferior to chemoradiotherapy following induction chemotherapy for patients with locoregionally advanced nasopharyngeal carcinoma.
According to results from a phase 3 trial, radiotherapy alone was noninferior to chemoradiotherapy following induction chemotherapy for patients with locoregionally advanced nasopharyngeal carcinoma.
According to results from a...
02/23/2024
Oncology
News
Benefit From Postoperative Radiotherapy Improves With Increasing Tumor Size Among Patients with Oral Cavity Squamous Cell Carcinoma
02/13/2024
Allison Casey
According to a retrospective analysis, postoperative radiotherapy was associated with improved overall survival among patients with pT4aN0 oral cavity squamous cell carcinoma, and the relative survival benefit improved with increasing tumor...
According to a retrospective analysis, postoperative radiotherapy was associated with improved overall survival among patients with pT4aN0 oral cavity squamous cell carcinoma, and the relative survival benefit improved with increasing tumor...
According to a retrospective...
02/13/2024
Oncology
News
Streptococcus salivarius K12 Probiotic Reduced Severe Radiation-Associated Oral Mucositis Among Patients With Head and Neck Cancer
02/08/2024
Allison Casey
In this prospective, randomized, double-blind clinical trial, S. salivarius K12 reduced the incidence, onset, and duration of severe oral mucositis among patients undergoing radiotherapy for head and neck cancer.
In this prospective, randomized, double-blind clinical trial, S. salivarius K12 reduced the incidence, onset, and duration of severe oral mucositis among patients undergoing radiotherapy for head and neck cancer.
In this prospective, randomized,...
02/08/2024
Oncology
News
Omitting Frontline Chemotherapy Lowers Toxicity Without Sacrificing Survival in Oligometastatic Head and Neck Cancer
11/02/2023

Janelle Bradley

Janelle Bradley
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with...
11/02/2023
Oncology
News
Toripalimab Approved for First-Line Treatment of Patients With Nasopharyngeal Carcinoma
10/31/2023
Allison Casey
On October 30, 2023, the FDA granted approval to toripalimab, with cisplatin and gemcitabine, for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma in the first-line setting.
On October 30, 2023, the FDA granted approval to toripalimab, with cisplatin and gemcitabine, for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma in the first-line setting.
On October 30, 2023, the FDA...
10/31/2023
Oncology
News
Tipifarnib for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With HRAS Mutations
10/31/2023

Stephanie Holland 

Stephanie Holland 
According to results from AIN-HN study, tipifarnib is safe, tolerable, and demonstrated anti-tumor activity n later-line settings among patients with HRAS-mutated recurrent or metastatic head and neck squamous cell carcinoma who had received...
According to results from AIN-HN study, tipifarnib is safe, tolerable, and demonstrated anti-tumor activity n later-line settings among patients with HRAS-mutated recurrent or metastatic head and neck squamous cell carcinoma who had received...
According to results from AIN-HN...
10/31/2023
Oncology

Advertisement

News

News
First-Line Pembrolizumab Plus Chemotherapy Showed Promise Among Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/26/2024
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the...
07/26/2024
Oncology
Conference Coverage
Addition of Nivolumab to Triple Metronomic Chemotherapy Significantly Improved Overall Survival Among Patients With Advanced Head and Neck Squamous Cell Carcinoma
06/20/2024

Stephanie Holland 

Stephanie Holland 
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose...
06/20/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
Conference Coverage
Tisotumab Vedotin Showed Promising Clinical Activity Among Heavily Pretreated Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
06/11/2024

Stephanie Holland 

Stephanie Holland 
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results...
06/11/2024
Oncology
News
Addition of Vismodegib to Radiation Therapy Shows Promise Among Patients With Basal Cell Carcinoma
05/10/2024

Stephanie Holland 

Stephanie Holland 
Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.
Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.
Results from a prospective,...
05/10/2024
Oncology
News
Radiotherapy Alone After Chemotherapy Induction for Patients With Nasopharyngeal Carcinoma
02/23/2024

Allison Casey

Allison Casey
According to results from a phase 3 trial, radiotherapy alone was noninferior to chemoradiotherapy following induction chemotherapy for patients with locoregionally advanced nasopharyngeal carcinoma.
According to results from a phase 3 trial, radiotherapy alone was noninferior to chemoradiotherapy following induction chemotherapy for patients with locoregionally advanced nasopharyngeal carcinoma.
According to results from a...
02/23/2024
Oncology
News
Benefit From Postoperative Radiotherapy Improves With Increasing Tumor Size Among Patients with Oral Cavity Squamous Cell Carcinoma
02/13/2024
Allison Casey
According to a retrospective analysis, postoperative radiotherapy was associated with improved overall survival among patients with pT4aN0 oral cavity squamous cell carcinoma, and the relative survival benefit improved with increasing tumor...
According to a retrospective analysis, postoperative radiotherapy was associated with improved overall survival among patients with pT4aN0 oral cavity squamous cell carcinoma, and the relative survival benefit improved with increasing tumor...
According to a retrospective...
02/13/2024
Oncology
News
Streptococcus salivarius K12 Probiotic Reduced Severe Radiation-Associated Oral Mucositis Among Patients With Head and Neck Cancer
02/08/2024
Allison Casey
In this prospective, randomized, double-blind clinical trial, S. salivarius K12 reduced the incidence, onset, and duration of severe oral mucositis among patients undergoing radiotherapy for head and neck cancer.
In this prospective, randomized, double-blind clinical trial, S. salivarius K12 reduced the incidence, onset, and duration of severe oral mucositis among patients undergoing radiotherapy for head and neck cancer.
In this prospective, randomized,...
02/08/2024
Oncology
News
Omitting Frontline Chemotherapy Lowers Toxicity Without Sacrificing Survival in Oligometastatic Head and Neck Cancer
11/02/2023

Janelle Bradley

Janelle Bradley
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with...
11/02/2023
Oncology
News
Toripalimab Approved for First-Line Treatment of Patients With Nasopharyngeal Carcinoma
10/31/2023
Allison Casey
On October 30, 2023, the FDA granted approval to toripalimab, with cisplatin and gemcitabine, for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma in the first-line setting.
On October 30, 2023, the FDA granted approval to toripalimab, with cisplatin and gemcitabine, for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma in the first-line setting.
On October 30, 2023, the FDA...
10/31/2023
Oncology

Interactive Features

Quiz
Quiz: Docetaxel Plus Radiotherapy For Cisplatin-Ineligible Patients With Head and Neck Carcinoma
09/02/2022
In a study evaluating the addition of docetaxel to radiotherapy for head and neck squamous cell carcinoma, which outcome was improved with docetaxel compared to radiation alone? Test your knowledge with our quiz.
In a study evaluating the addition of docetaxel to radiotherapy for head and neck squamous cell carcinoma, which outcome was improved with docetaxel compared to radiation alone? Test your knowledge with our quiz.
In a study evaluating the...
09/02/2022
Oncology
Test Your Knowledge
Quiz: Single Agent Vs Combo Therapy for Cetuximab in CRC, Head and Neck Cancer
04/22/2021
True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
True or False: Cetuximab, a...
04/22/2021
Oncology
Test Your Knowledge
Quiz: Is Lenvatinib a Second-Line Treatment Option for Patients with Thymic Carcinoma?
07/30/2020
True or False: Recent findings suggest that lenvatinib is a potential treatment option for patients with previously treated advanced or metastatic thymic carcinoma.
True or False: Recent findings suggest that lenvatinib is a potential treatment option for patients with previously treated advanced or metastatic thymic carcinoma.
True or False: Recent findings...
07/30/2020
Oncology
Test Your Knowledge
Quiz: Is Age Tied to Disease Progression in Adults With Papillary Thyroid Cancer?
07/13/2020
07/13/2020
Oncology
Test Your Knowledge
Quiz: Late-Line Bemarituzumab Therapy for Advanced Gastroesophageal Cancer
05/22/2020
True or False: Late-line bemarituzumab has been shown to be active and well-tolerated in patients with advanced FGFR2b-overexpressing gastric and GEA.
True or False: Late-line bemarituzumab has been shown to be active and well-tolerated in patients with advanced FGFR2b-overexpressing gastric and GEA.
True or False: Late-line...
05/22/2020
Oncology
Test Your Knowledge
Quiz: Can Acupuncture Prevent Xerostomia in Head and Neck Cancer?
03/02/2020
True or False: Acupuncture may prevent radiation-induced xerostomia in patients with head and neck cancer.
True or False: Acupuncture may prevent radiation-induced xerostomia in patients with head and neck cancer.
True or False: Acupuncture may...
03/02/2020
Oncology
Test Your Knowledge
Quiz: Adding Which Drug to This Combo Therapy Improves Nasopharyngeal Carcinoma Outcomes?
11/08/2019
Adding which drug to cisplatin and chemoradiotherapy improved survival in patients with nasopharyngeal carcinoma?
Adding which drug to cisplatin and chemoradiotherapy improved survival in patients with nasopharyngeal carcinoma?
Adding which drug to cisplatin...
11/08/2019
Oncology
Test Your Knowledge
Quiz: Temozolomide Combo for MGMT-Methylated Glioblastoma
10/01/2019
Which drug plus temozolomide is clinically beneficial for newly diagnosed MGMT-methylated glioblastoma?
Which drug plus temozolomide is clinically beneficial for newly diagnosed MGMT-methylated glioblastoma?
Which drug plus temozolomide is...
10/01/2019
Oncology
Test Your Knowledge
Quiz: Palbociclib and Cetuximab as Therapy for HPV-Unrelated HNSCC
08/29/2019
True or False: Palbociclib and cetuximab therapy has shown promising activity in patients with HPV-unrelated, platinum- or cetuximab-resistant, head and neck squamous-cell carcinomas.
True or False: Palbociclib and cetuximab therapy has shown promising activity in patients with HPV-unrelated, platinum- or cetuximab-resistant, head and neck squamous-cell carcinomas.
True or False: Palbociclib and...
08/29/2019
Oncology
Test Your Knowledge
Quiz: Risk for Brain Metastases Higher With Twice-Daily Radiotherapy for SCLC?
08/01/2019
True or false: Patients with SCLC undergoing radiotherapy twice daily are more likely to have brain metastases after prophylactic cranial irradiation than those given radiotherapy once daily.
True or false: Patients with SCLC undergoing radiotherapy twice daily are more likely to have brain metastases after prophylactic cranial irradiation than those given radiotherapy once daily.
True or false: Patients with...
08/01/2019
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
First-Line Pembrolizumab Plus Chemotherapy Showed Promise Among Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/26/2024
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the...
07/26/2024
Oncology
Conference Coverage
Addition of Nivolumab to Triple Metronomic Chemotherapy Significantly Improved Overall Survival Among Patients With Advanced Head and Neck Squamous Cell Carcinoma
06/20/2024

Stephanie Holland 

Stephanie Holland 
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose...
06/20/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
Conference Coverage
Tisotumab Vedotin Showed Promising Clinical Activity Among Heavily Pretreated Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
06/11/2024

Stephanie Holland 

Stephanie Holland 
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results...
06/11/2024
Oncology
News
Addition of Vismodegib to Radiation Therapy Shows Promise Among Patients With Basal Cell Carcinoma
05/10/2024

Stephanie Holland 

Stephanie Holland 
Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.
Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.
Results from a prospective,...
05/10/2024
Oncology
News
Radiotherapy Alone After Chemotherapy Induction for Patients With Nasopharyngeal Carcinoma
02/23/2024

Allison Casey

Allison Casey
According to results from a phase 3 trial, radiotherapy alone was noninferior to chemoradiotherapy following induction chemotherapy for patients with locoregionally advanced nasopharyngeal carcinoma.
According to results from a phase 3 trial, radiotherapy alone was noninferior to chemoradiotherapy following induction chemotherapy for patients with locoregionally advanced nasopharyngeal carcinoma.
According to results from a...
02/23/2024
Oncology
News
Benefit From Postoperative Radiotherapy Improves With Increasing Tumor Size Among Patients with Oral Cavity Squamous Cell Carcinoma
02/13/2024
Allison Casey
According to a retrospective analysis, postoperative radiotherapy was associated with improved overall survival among patients with pT4aN0 oral cavity squamous cell carcinoma, and the relative survival benefit improved with increasing tumor...
According to a retrospective analysis, postoperative radiotherapy was associated with improved overall survival among patients with pT4aN0 oral cavity squamous cell carcinoma, and the relative survival benefit improved with increasing tumor...
According to a retrospective...
02/13/2024
Oncology
News
Streptococcus salivarius K12 Probiotic Reduced Severe Radiation-Associated Oral Mucositis Among Patients With Head and Neck Cancer
02/08/2024
Allison Casey
In this prospective, randomized, double-blind clinical trial, S. salivarius K12 reduced the incidence, onset, and duration of severe oral mucositis among patients undergoing radiotherapy for head and neck cancer.
In this prospective, randomized, double-blind clinical trial, S. salivarius K12 reduced the incidence, onset, and duration of severe oral mucositis among patients undergoing radiotherapy for head and neck cancer.
In this prospective, randomized,...
02/08/2024
Oncology
News
Omitting Frontline Chemotherapy Lowers Toxicity Without Sacrificing Survival in Oligometastatic Head and Neck Cancer
11/02/2023

Janelle Bradley

Janelle Bradley
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with...
11/02/2023
Oncology
News
Toripalimab Approved for First-Line Treatment of Patients With Nasopharyngeal Carcinoma
10/31/2023
Allison Casey
On October 30, 2023, the FDA granted approval to toripalimab, with cisplatin and gemcitabine, for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma in the first-line setting.
On October 30, 2023, the FDA granted approval to toripalimab, with cisplatin and gemcitabine, for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma in the first-line setting.
On October 30, 2023, the FDA...
10/31/2023
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement